Inhibrx Biosciences Inc
1 位超级投资者持有 Inhibrx Biosciences Inc(INBX)。
仅供教育与信息参考,不构成投资建议。13F 持仓为机构自行申报,可能滞后最多 45 天。
估值 · 地基层
Inhibrx Biosciences Inc (INBX): A conservative earnings-power estimate, $281–$407 / sh; today’s price sits below it (price $95 as of 2026-06-25).
Model cautions
- ·Owner-earnings yield diverges sharply from the 10-year Treasury (over 300 bps).
An observation from two valuation methods — not investment advice, not a buy/sell signal, and not a price target.
Price as of 2026-06-25 · yahoo · DGS10 4.4% @ 2026-06-24.
Method & numbers
Owner-earnings DCF $281.49 – $407.37 · Greenwald zero-growth $351.86 · zero-growth base $351.86 · reproduction $25.76
Moat Below asset base · terminal value 44% of present value · owner-earnings yield 30% vs 10Y 4.4%.
Graham earnings-power value (normalized NOPAT)
Normalized operating earnings net of maintenance capex are non-positive over the years shown; earnings power cannot be capitalized.
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 8–10% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
Years: 2025, 2024, 2023
v1 simplifications: Maintenance capex (degraded) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Maintenance-capex methods diverge by 148% (> 50%); estimate is degraded. Share-based compensation is left as a real expense (not added back).
Buffett owner-earnings value$281.49 – $351.86 / sh
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 8–10% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
Years: 2025, 2024, 2023
v1 simplifications: Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the same 8–10% band as a cost-of-equity proxy (theoretically the cost of equity is higher; v2 simplification, v3 to refine).
Reproduction value = tangible net assets $7.99M + capitalized R&D $391.01M (FY 2025, 2024, 2023) = $25.76 / sh. Total book value (equity ÷ diluted shares) + capitalized R&D; intangibles not separated — goodwill/intangibles unavailable this period.
Moat reading: Franchise test compares earnings power (EPV) against reproduction value (tangible net assets + capitalized R&D). EPV well above reproduction value signals a moat; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
Growth value gated to zero — no moat / ROIIC ≤ WACC, so no growth value is credited.
Window FY 2025, 2024, 2023 · discount band 8%–10% · normalized tax 0% (Average effective tax rate over 3 year(s), capped at the statutory 21%.) · diluted shares.
Owner-earnings DCF: growth g₁ 0% · OE FY 2025, 2024, 2023 · Discount band: 6.91%–10.00% (DGS10 +2.5% to a 10% strict end, as of 2026-06-24). No enterprise→equity bridge: owner earnings already flow to shareholders (post-interest), so no net cash is added and no debt subtracted — matching the engine owner-earnings lamp.
持有该证券的超级投资者
| 投资人 | 市值 | 持股 | 权重(上季→本季) |
|---|---|---|---|
| Andreas Halvorsen | $96.7M | 1,437,705 | 0.3% → 0.3% |
- 市值$96.7M权重(上季→本季)0.3% → 0.3%
持有概览
›
Inhibrx Biosciences Inc(INBX)被 Compounder 追踪的 1 位超级投资者持有,合计申报市值 $96.7M。仓位最大的是 Andreas Halvorsen,占其组合 0.3%。
以上持有人数与市值来自最新的 SEC Form 13F 申报,截至 2026-03-31 季度。来源:SEC EDGAR。13F 仅涵盖美股多头持仓,且可能滞后实际组合最多 45 天,因此这是已披露的多头持有情况,并非完整全貌。
持有人趋势
›
近 8 季持有该证券的超级投资者:1 → 1 家。
早期季度持有人数可能因数据回填偏低,斜率仅供参考。
数据来源· SEC EDGAR 13F 截至 2026-05-15
订阅更新
每期精选 13F 异动与估值洞察,直达你的邮箱。